Transdermal Oestradiol Patches Non-inferior to LHRH Agonists Regarding Metastasis-Free Survival in Patients with Locally Advanced Prostate Cancer By Ogkologos - April 16, 2026 133 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a phase III study in patients recruited through the PATCH and STAMPEDE-1 trial networks Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Palbociclib with Trastuzumab, With or Without Pertuzumab, and Endocrine Therapy for the Maintenance Treatment of HR-positive, HER2-positive LA/MBC Peptide Receptor Radionuclide Therapy [177Lu]Lu-Edotreotide Prolongs PFS in Patients with Advanced, Progressive, Somatostatin Receptor-Positive GEP NETs Ensartinib Improves DFS Outcomes in Patients with ALK-positive, Completely Resected Stage II to IIIB NSCLC MOST POPULAR Cancer in My Community: Developing Pediatric Palliative and Supportive Care in... January 16, 2024 Targeted Therapy for Claudin-18.2 and Combined PD-1 and TIGIT Immunotherapy for... November 6, 2023 How to Tell If Cancer Information on Social Media Is “Fake... September 29, 2020 Patients less likely to rate cancer care as ‘very good’ during... August 4, 2021 Load more HOT NEWS Noninferiority of OS with 3 Months Compared to 6 Months of... Teacher Visits Student Battling Cancer At Home To Help With His... Father Dances With Joy After Learning His Son Is Cancer Free Atezolizumab Approved for Initial Treatment of Metastatic Lung Cancer
